| Schedule of Prepaid Expenses and Other Current Assets |
Prepaid expenses and other current assets are as follows (in thousands): | | | | | | | | | | | | | Description | June 30, 2026 | | December 31, 2025 | | | | | Restricted cash | $ | 1,708 | | | $ | 1,699 | | | Other | 5,773 | | | 3,771 | | | Total prepaid expenses and other current assets | $ | 7,481 | | | $ | 5,470 | |
|
| Schedule of Other Long-Term Assets |
Other long-term assets are as follows (in thousands): | | | | | | | | | | | | | Description | June 30, 2026 | | December 31, 2025 | | Long-term inventories | $ | 53,272 | | | $ | 59,129 | | | | | | | Other | 475 | | | 552 | | | Total other long-term assets | $ | 53,747 | | | $ | 59,681 | |
|
| Schedule of Components of Accrued Expenses and Other Current Liabilities |
Accrued expenses and other current liabilities are as follows (in thousands): | | | | | | | | | | | | Description | June 30, 2026 | | December 31, 2025 | | Product revenue allowances excluding rebates | $ | 5,568 | | | $ | 7,916 | | | Product rebates | 68,893 | | | 64,674 | | | Product return provisions, current portion | 1,694 | | | 2,375 | | | Clinical trial costs | 1,446 | | | 1,188 | | | Compensation and related benefits | 7,348 | | | 11,018 | | | Operating lease liabilities | 1,006 | | | 3,548 | | | Royalties due to Panion & BF Biotech, Inc. | 2,458 | | | 3,924 | | | Professional fees | 1,572 | | | 1,597 | | | Accrued manufacturing costs | 2,362 | | | 1,808 | | | Restructuring costs | 1,688 | | | — | | | Liability related to sale of future royalties, current portion | 1,450 | | | 1,664 | | | Settlement royalties liability, current portion | 9,624 | | | 12,516 | | | Payments due to Q32 Bio Inc. | 2,000 | | | 5,000 | | | Other | 2,688 | | | 4,488 | | | Total accrued expenses and other current liabilities | $ | 109,797 | | | $ | 121,716 | |
|